Cargando…
Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer
Colorectal cancer (CRC) is one of the most common cancers, with a high mortality rate, and is a major burden on human health worldwide. Gut microbiota regulate human immunity and metabolism through producing numerous metabolites, which act as signaling molecules and substrates for metabolic reaction...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927011/ https://www.ncbi.nlm.nih.gov/pubmed/36798129 http://dx.doi.org/10.3389/fimmu.2023.1128774 |
_version_ | 1784888393802448896 |
---|---|
author | Yuan, Hanghang Gui, Ruirui Wang, Zhicheng Fang, Fang Zhao, Hongguang |
author_facet | Yuan, Hanghang Gui, Ruirui Wang, Zhicheng Fang, Fang Zhao, Hongguang |
author_sort | Yuan, Hanghang |
collection | PubMed |
description | Colorectal cancer (CRC) is one of the most common cancers, with a high mortality rate, and is a major burden on human health worldwide. Gut microbiota regulate human immunity and metabolism through producing numerous metabolites, which act as signaling molecules and substrates for metabolic reactions in various biological processes. The importance of host-gut microbiota interactions in immunometabolic mechanisms in CRC is increasingly recognized, and interest in modulating the microbiota to improve patient’s response to therapy has been raising. However, the specific mechanisms by which gut microbiota interact with immunotherapy and radiotherapy remain incongruent. Here we review recent advances and discuss the feasibility of gut microbiota as a regulatory target to enhance the immunogenicity of CRC, improve the radiosensitivity of colorectal tumor cells and ameliorate complications such as radiotoxicity. Currently, great breakthroughs in the treatment of non-small cell lung cancer and others have been achieved by radioimmunotherapy, but radioimmunotherapy alone has not been effective in CRC patients. By summarizing the recent preclinical and clinical evidence and considering regulatory roles played by microflora in the gut, such as anti-tumor immunity, we discuss the potential of targeting gut microbiota to enhance the efficacy of radioimmunotherapy in CRC and expect this review can provide references and fresh ideas for the clinical application of this novel strategy. |
format | Online Article Text |
id | pubmed-9927011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99270112023-02-15 Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer Yuan, Hanghang Gui, Ruirui Wang, Zhicheng Fang, Fang Zhao, Hongguang Front Immunol Immunology Colorectal cancer (CRC) is one of the most common cancers, with a high mortality rate, and is a major burden on human health worldwide. Gut microbiota regulate human immunity and metabolism through producing numerous metabolites, which act as signaling molecules and substrates for metabolic reactions in various biological processes. The importance of host-gut microbiota interactions in immunometabolic mechanisms in CRC is increasingly recognized, and interest in modulating the microbiota to improve patient’s response to therapy has been raising. However, the specific mechanisms by which gut microbiota interact with immunotherapy and radiotherapy remain incongruent. Here we review recent advances and discuss the feasibility of gut microbiota as a regulatory target to enhance the immunogenicity of CRC, improve the radiosensitivity of colorectal tumor cells and ameliorate complications such as radiotoxicity. Currently, great breakthroughs in the treatment of non-small cell lung cancer and others have been achieved by radioimmunotherapy, but radioimmunotherapy alone has not been effective in CRC patients. By summarizing the recent preclinical and clinical evidence and considering regulatory roles played by microflora in the gut, such as anti-tumor immunity, we discuss the potential of targeting gut microbiota to enhance the efficacy of radioimmunotherapy in CRC and expect this review can provide references and fresh ideas for the clinical application of this novel strategy. Frontiers Media S.A. 2023-01-31 /pmc/articles/PMC9927011/ /pubmed/36798129 http://dx.doi.org/10.3389/fimmu.2023.1128774 Text en Copyright © 2023 Yuan, Gui, Wang, Fang and Zhao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Yuan, Hanghang Gui, Ruirui Wang, Zhicheng Fang, Fang Zhao, Hongguang Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer |
title | Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer |
title_full | Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer |
title_fullStr | Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer |
title_full_unstemmed | Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer |
title_short | Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer |
title_sort | gut microbiota: a novel and potential target for radioimmunotherapy in colorectal cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927011/ https://www.ncbi.nlm.nih.gov/pubmed/36798129 http://dx.doi.org/10.3389/fimmu.2023.1128774 |
work_keys_str_mv | AT yuanhanghang gutmicrobiotaanovelandpotentialtargetforradioimmunotherapyincolorectalcancer AT guiruirui gutmicrobiotaanovelandpotentialtargetforradioimmunotherapyincolorectalcancer AT wangzhicheng gutmicrobiotaanovelandpotentialtargetforradioimmunotherapyincolorectalcancer AT fangfang gutmicrobiotaanovelandpotentialtargetforradioimmunotherapyincolorectalcancer AT zhaohongguang gutmicrobiotaanovelandpotentialtargetforradioimmunotherapyincolorectalcancer |